Abstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
All Keywords
【초록키워드】 COVID-19, Treatment, Hospitalized, thrombosis, hospitalized patients, Venous Thromboembolism, therapeutic, Research, incidence, Care, critically ill patients, randomized control trial, syndrome, recommendation, benefit, include, hospitalized patient, ill patient, with COVID-19, 【제목키워드】 hospitalized patient, with COVID-19,
【초록키워드】 COVID-19, Treatment, Hospitalized, thrombosis, hospitalized patients, Venous Thromboembolism, therapeutic, Research, incidence, Care, critically ill patients, randomized control trial, syndrome, recommendation, benefit, include, hospitalized patient, ill patient, with COVID-19, 【제목키워드】 hospitalized patient, with COVID-19,